drugset / Trial / NCT06222593
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI) and experienced disease progression.
Timeline
- Start
- 2024-10-01
- Primary completion
- 2026-07-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | 50 mg | Oral |
| Subject | Sunitinib | Small molecule | 25 mg | — |
| Subject | Sunitinib | Small molecule | 37.5 mg | — |
| Subject | Sunitinib | Small molecule | 50 mg | — |